Introduction to Abbott and its New Plant
Abbott, a prominent American company, has inaugurated its new electrophysiology manufacturing plant in Querétaro, Mexico. The company invested $200 million in this project.
Plant Operations and Product Focus
The plant will produce high-precision electrophysiology devices used in minimally invasive procedures to restore healthy heart rhythms. These devices include diagnostic and mapping catheters for arrhythmia, therapeutic catheters, and vascular access systems.
- The products will cater to both national and international markets, with initial exports going to the United States, Europe, Canada, Japan, and Australia.
- The plant will initially employ 300 workers, with an expectation to grow to 1,200 by 2030.
Significance of Electrophysiology Devices
Electrophysiology, a highly advanced specialty within cardiology, focuses on the heart’s electrical system. It enables diagnosis and treatment of arrhythmias, such as atrial fibrillation, a common condition that can lead to sudden cardiac arrest, stroke, or heart failure.
Initially, the plant will manufacture mapping and imaging catheters introduced into the heart to record its electrical signals and generate 3D maps identifying arrhythmia origins. Abbott plans to expand production to include catheters for minimally invasive procedures.
Abbott’s Commitment to Mexico
Robert Ford, Abbott’s CEO, explained that the investment in Querétaro positions the company as the first manufacturer of health technologies in Mexico.
“We could have built this plant almost anywhere, but we chose to grow here in Mexico because of our long history here and the exceptional business environment,” Ford said.
Currently, Abbott employs 1,400 people in Mexico and anticipates doubling this number due to the new Querétaro plant’s growth projections.
Government Officials’ Reactions
During the plant inauguration, David Kershenobich Stalnikowitz, Mexico’s Secretary of Health, highlighted that the development of such a plant underscores Mexico’s technical capabilities and positions it as an attractive location for highly specialized industries.
He also mentioned that the devices produced will strengthen cardiovascular care, addressing high-risk conditions like atrial fibrillation, which is prevalent in Mexico and linked to significant diseases.
Marco Antonio Del Prete Tercero, Querétaro’s Secretary of Sustainable Development, noted that this investment project has been underway for four years and now marks the state’s entry into a new industry.
Abbott’s Background
Abbott has been present in the Mexican market since 1934, starting with 20 salespeople and beginning manufacturing in the country in 1936. Globally, Abbott operates 90 manufacturing facilities and employs 115,000 people.
